TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2017 Financial Results Investor Conference Call to be Held Today, Wednesday

TG Therapeutics, Inc. Provides Business Update and Reports Second

Quarter 2017 Financial Results

Investor Conference Call to be Held Today, Wednesday, August 9,

York, NY, (August 9, 2017)

TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its

financial results for the second quarter ended June 30, 2017 and

recent company developments.

S. Weiss, the Company's Executive Chairman and Chief Executive

Officer, stated, "The second quarter was a busy and exciting time

for the Company, with the full presentation of the GENUINE data at

ASCO coupled with additional important data presentations for

TGR-1202 in various combinations. In addition, we were pleased to

announce a successful outcome to the interim analysis in the

UNITY-CLL program, allowing us to drop the two single agent arms

and confirming that there were no safety issues requiring a

modification of the trial. The UNITY-CLL study continues to enroll

very robustly and we look forward to completing enrollment into the

study by the end of the year. Mr. Weiss continued, "For the

remainder of the year we look forward to our discussions with the

FDA around the positive GENUINE Phase 3 results and the imminent

commencement of the Phase 3 program of TG-1101 in RMS, for which we

recently announced an SPA agreement with the

Recent Developments and Highlights

data from the Phase 3 GENUINE Trial of

TG-1101 in combination with Ibrutinib in patients with high risk

Chronic Lymphocytic Leukemia (CLL)

follow-up data for combination of

TGR-1202(umbralisib) plus

Ibrutinib in patients with relapsed or refractory CLL and Mantle

follow-up data for the triple

combination of TG-1101, TGR-1202, and Bendamustine in patients with

follow-up data from the chemo-free

triple combination of TG-1101, TGR-1202, and

the successful outcome from the pre-planned interim analysis by an

independent DSMB in the UNITY-CLL Phase 3 Trial which allowed for

closing of enrollment to the single agent arms in this

preliminary data from the ongoing Phase 2 study of TG-1101 in

patients with Multiple Sclerosis (MS)

a Special Protocol Assessment (SPA) agreement with the FDA for a

Phase 3 program for TG-1101 in relapsing forms of MS

Key Remaining 2017 Milestones

interim analysis in the UNITY-NHL trial for the DLBCL

Phase 3 program in MS, to be conducted under SPA agreement with the

clinical data from the Phase 2 MS trial

to review the GENUINE Phase 3 data and discuss suitability for

filing for accelerated approval

updated data from ongoing trials at various scientific meetings

throughout the year, including the American Society of Hematology

(ASH) annual meeting in December

Financial Results for the Second Quarter 2017

Cash, cash equivalents, investment

securities, and interest receivable were $86.5 million as of June

30, 2017. Pro-forma cash, cash equivalents, investment

securities, and interest receivable as of June 30, 2017 are

approximately $97.4 million, after giving effect to $10.9 million

of net proceeds from the utilization of the Company's

at-the-market ( ATM ) sales facility during the third

Research and development (R&D)

expenses were $26.7 million and $49.4 million for the three and six

months ended June 30, 2017, respectively, compared to $13.5 million

and $25.2 million for the three and six months ended June 30, 2016.

Included in research and development expense for the three and six

months ended June 30, 2017 was $8.1 million and $13.3 million,

respectively, of manufacturing and CMC expenses for Phase 3

clinical trials and potential commercialization, and $2.4 million

and $3.4 million, respectively, in expenses related to commencement

of the Phase 3 program for TG-1101 in MS. The increase in R&D

expenses for both the three and six months ended June 30, 2017, is

primarily due to the ongoing clinical development programs,

including the start-up costs in preparation for the TG-1101 MS

Phase 3 program, as well as manufacturing costs for both TG-1101

General and administrative (G&A)

expenses were $1.8 million and $6.8 million for the three and six

months ended June 30, 2017, respectively, as compared to $2.5

million and $4.9 million for the three and six months ended June

30, 2016. The increase in G&A expenses for the six months ended

June 30, 2017 relates primarily to non-cash compensation

expenses related to equity incentive grants recognized during 2017.

We expect G&A expenses to remain

relatively constant through the remainder of

Net Loss: Net loss was $28.4 million and $56.1 million for

the three and six months ended June 30, 2017, respectively,

compared to a net loss of $15.9 million and $29.7 million for the

three and six months ended June 30, 2016,

The Company believes its cash, cash

equivalents, investment securities, and interest receivable

inclusive of the proceeds raised subsequent to the quarter-end will

be sufficient to fund the Company's planned operations

Conference Call Information

Company will host an investor conference call today, August 9,

2017, at 8:30am ET, to discuss the Company's second quarter

2017 financial results and provide a business outlook for the

order to participate in the conference call, please call

1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.),

Conference Title: TG Therapeutics Second Quarter 2017 Earnings

Call. A live webcast of this presentation will be available on the

Events page, located within the Investors & Media section, of

the Company's website at www.tgtherapeutics.com. An audio recording

of the conference call will also be available for replay at

www.tgtherapeutics.com, for a period of 30 days after the